Nguyen, Hong PhuongLiu, EnzeLe, Anh QuynhLamsal, MaheshMisra, JagannathSrivastava, SankalpHemavathy, HarikrishnanKapur, ReubenZaid, Mohammad AbuAbonour, RafatZhang, JiWek, Ronald C.Walker, Brian A.Tran, Ngoc Tung2025-05-142025-05-142025-03-08Nguyen HP, Liu E, Le AQ, et al. The oligosaccharyltransferase complex is an essential component of multiple myeloma plasma cells. Mol Ther Oncol. 2025;33(2):200964. Published 2025 Mar 8. doi:10.1016/j.omton.2025.200964https://hdl.handle.net/1805/48073Multiple myeloma (MM) is an incurable malignancy characterized by mutated plasma cell clonal expansion in the bone marrow, leading to severe clinical symptoms. Thus, identifying new therapeutic targets for MM is crucial. We identified the oligosaccharyltransferase (OST) complex as a novel vulnerability in MM cells. Elevated expression of this complex is associated with relapsed, high-risk MM, and poor prognosis. Disrupting the OST complex suppressed MM cell growth, induced cell-cycle arrest, and apoptosis. Combined inhibition with bortezomib synergistically eliminated MM cells in vitro and in vivo, via suppressing genes related to bortezomib-resistant phenotypes. Mechanistically, OST complex disruption downregulated MM pathological pathways (mTORC1 pathway, glycolysis, MYC targets, and cell cycle) and induced TRAIL-mediated apoptosis. Notably, MYC translation was robustly suppressed upon inhibiting the OST complex. Collectively, the OST complex presents a novel target for MM treatment, and combining its inhibition with bortezomib offers a promising approach for relapsed MM patients.en-USAttribution 4.0 InternationalN-glycosylationOligosaccharyltransferase complexMultiple myelomaBortezomib resistanceXenograft modelApoptosisCell-cycle arrestPost-translational modificationArticle